Overrepresentation of transcription factor families in the genesets underlying breast cancer subtypes

BackgroundThe human genome contains a large amount of cis-regulatory DNA elements responsible for directing both spatial and temporal gene-expression patterns. Previous studies have shown that based on their mRNA expression breast tumors could be divided into five subgroups (Luminal A, Luminal B, Basal, ErbB2+ and Normal-like), each with a distinct molecular portrait. Whole genome gene expression analysis of independent sets of breast tumors reveals repeatedly the robustness of this classification. Furthermore, breast tumors carrying a TP53 mutation show a distinct gene expression profile, which is in strong association to the distinct molecular portraits. The mRNA expression of 552 genes, which varied considerably among the different tumors, but little between two samples of the same tumor, has been shown to be sufficient to separate these tumor subgroups.ResultsWe analyzed in silico the transcriptional regulation of genes defining the subgroups at 3 different levels: 1. We studied the pathways in which the genes distinguishing the subgroups of breast cancer may be jointly involved including upstream regulators (1st and 2nd level of regulation) as well as downstream targets of these genes. 2. Then we analyzed the promoter areas of these genes (−500 bp to +100 bp relative to the transcription start site) for canonical transcription binding sites using Genomatix. 3. We looked for the actual expression levels of the identified TF and how they correlate with the overrepresentation of their TF binding sites in the separate groups. We report that promoter composition of the genes that most strongly predict the patient subgroups is distinct. The class-predictive genes showed a clearly different degree of overrepresentation of transcription factor families in their promoter sequences.ConclusionThe study suggests that transcription factors responsible for the observed expression pattern in breast cancers may lead us to important biological pathways.

[1]  Olivier Bodenreider,et al.  The biological function of some human transcription factor binding motifs varies with position relative to the transcription start site , 2008, Nucleic acids research.

[2]  J. Cusack,et al.  Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB , 1999, Nature Medicine.

[3]  Jeffery Y C Wong,et al.  Expression of ErbB2 enhances radiation-induced NF-kappaB activation. , 2004, Oncogene.

[4]  Sven Bilke,et al.  Transcriptional networks inferred from molecular signatures of breast cancer. , 2008, The American journal of pathology.

[5]  S. Razin,et al.  Association of the mammalian transcriptional regulator Kaiso with centrosomes and the midbody , 2009, Cell cycle.

[6]  Thomas Werner,et al.  MatInspector and beyond: promoter analysis based on transcription factor binding sites , 2005, Bioinform..

[7]  D. Frank.  STAT3 as a central mediator of neoplastic cellular transformation. , 2007, Cancer letters.

[8]  Alexander E. Kel,et al.  COMPEL: a database on composite regulatory elements providing combinatorial transcriptional regulation , 2000, Nucleic Acids Res..

[9]  T. Sørlie,et al.  Evaluation of MetriGenix custom 4D™ arrays applied for detection of breast cancer subtypes , 2006, BMC Cancer.

[10]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Gerstein,et al.  Genomic analysis of regulatory network dynamics reveals large topological changes , 2004, Nature.

[12]  M. Mansukhani,et al.  Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study , 2009, Modern Pathology.

[13]  K. Vousden,et al.  Role of NF-kappaB in p53-mediated programmed cell death. , 2000, Nature.

[14]  K. Gardner,et al.  Identification of new Rel/NFκB regulatory networks by focused genome location analysis , 2009, Cell cycle.

[15]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Debajit K. Biswas,et al.  NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis , 2004 .

[17]  Daxi Sun,et al.  Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1* , 2001, The Journal of Biological Chemistry.

[18]  Jürgen Dittmer,et al.  Molecular Cancer BioMed Central Review The Biology of the Ets1 Proto-Oncogene , 2003 .

[19]  W. Woods,et al.  Identification and characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 and p53, respectively. , 2004, The Journal of biological chemistry.

[20]  Jeffery Y C Wong,et al.  Expression of ErbB2 enhances radiation-induced NF-κB activation , 2004, Oncogene.

[21]  A. Ray,et al.  Repression of interleukin‐6 gene expression by 17β‐estradiol: , 1997 .

[22]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[23]  Xianglin Shi,et al.  New Insights into the Role of Nuclear Factor-κB in Cell Growth Regulation , 2001 .

[24]  Thomas Werner,et al.  Functional promoter modules can be detected by formal models independent of overall nucleotide sequence similarity , 1999, Bioinform..

[25]  Thomas Werner,et al.  The next generation of literature analysis: Integration of genomic analysis into text mining , 2005, Briefings Bioinform..

[26]  Sergei Egorov,et al.  Pathway studio - the analysis and navigation of molecular networks , 2003, Bioinform..

[27]  D. H. Zhang,et al.  Repression of interleukin-6 gene expression by 17 beta-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor. , 1997, FEBS letters.

[28]  K. Vousden,et al.  Role of NF-κB in p53-mediated programmed cell death , 2000, Nature.

[29]  D. Roy,et al.  Estrogen-induced mitochondrial reactive oxygen species as signal-transducing messengers. , 2005, Biochemistry.

[30]  A. Ritchie,et al.  PAR bZIP-bik is a novel transcriptional pathway that mediates oxidative stress-induced apoptosis in fibroblasts , 2009, Cell Death and Differentiation.

[31]  Tsuneyuki Oikawa,et al.  ETS transcription factors: Possible targets for cancer therapy , 2004, Cancer science.

[32]  Toshiyuki Yamada,et al.  Molecular biology of the Ets family of transcription factors. , 2003, Gene.

[33]  V. Sementchenko,et al.  Ets target genes: past, present and future , 2000, Oncogene.

[34]  G. Church,et al.  Identifying regulatory networks by combinatorial analysis of promoter elements , 2001, Nature Genetics.

[35]  Q. Felty,et al.  Oncomine meta-analysis of breast cancer microarray data identifies upregulation of NRF-1 expression in human breast carcinoma , 2009 .

[36]  S. Simonsson,et al.  Phosphorylated Nucleolin Interacts with Translationally Controlled Tumor Protein during Mitosis and with Oct4 during Interphase in ES Cells , 2010, PloS one.

[37]  Sunjoo Jeong,et al.  NF-κB p65 represses β-catenin-activated transcription of cyclin D1. , 2010, Biochemical and biophysical research communications.

[38]  Heng Tao Shen,et al.  Principal Component Analysis , 2009, Encyclopedia of Biometrics.

[39]  Israel Steinfeld,et al.  miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors , 2011, PloS one.

[40]  R. Coffey,et al.  Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. , 2001, Oncogene.

[41]  David J. Arenillas,et al.  oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes , 2005, Nucleic acids research.

[42]  F. Chen,et al.  New insights into the role of nuclear factor-kappaB in cell growth regulation. , 2001, The American journal of pathology.

[43]  R. Sharan,et al.  Genome-wide in silico identification of transcriptional regulators controlling the cell cycle in human cells. , 2003, Genome research.

[44]  Y. Miki,et al.  DNA damage signalling recruits RREB-1 to the p53 tumour suppressor promoter. , 2009, The Biochemical journal.

[45]  T. Werner,et al.  Regulatory context is a crucial part of gene function. , 2002, Trends in genetics : TIG.

[46]  R. McKay,et al.  A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. , 2002, Genes & development.

[47]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.